Skip to main content
OpenTrials

Clinical trial condition

Pulmonary Fibrosis

Explore clinical trials studying Pulmonary Fibrosis. Study availability and eligibility vary by location and protocol.

374 public trials 55 recruiting studies
Refine in advanced search Browse all conditions

Pulmonary Fibrosis trial results

Completed

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

NCT04708782

Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Lung Diseases, +3 more
Locations
  • The University of Alabama at Birmingham Birmingham, Alabama, United States
  • Banner University Medical Center-Phoenix Phoenix, Arizona, United States
  • Arizona Pulmonary Specialists, Ltd. Phoenix, Arizona, United States
  • St. Joseph's Hospital and Medical Center - Norton Thoracic Institute Phoenix, Arizona, United States
View all 98 locations
View Trial Details
Completed

Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients

NCT05195918

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • UCSF Parnassus San Francisco, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • University of Michigan Ann Arbor, Michigan, United States
  • Weill Cornell Medicine New York, United States
View Trial Details
Completed

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

NCT06081621

Conditions
Idiopathic Pulmonary Fibrosis, Lung Diseases, Lung Diseases, Interstitial, +2 more
Locations
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing, Beijing Municipality, China
  • The Second Affiliated Hospital of Xiamen Medical College Xiamen, Fujian, China
  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine Shanghai, Shanghai Municipality, China
  • Renji Hospital, Shanghai Jiaotong University School Of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT03286556

Conditions
Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis, Acute Fatal Form, Lung Diseases, +3 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Dan Dilling Chicago, Illinois, United States
  • Thomas Jefferson University Medical Center Philadelphia, Pennsylvania, United States
  • Temple University Hospital Philadelphia, Pennsylvania, United States
View Trial Details

Related conditions